Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide
- PMID: 8956324
- DOI: 10.1023/a:1016472119387
Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide
Abstract
Purpose: To evaluate a cyclic acyloxyalkoxycarbamate prodrug of a model hexapeptide (H-Trp-Ala-Gly-Gly-Asp-Ala-OH) as a novel approach to enhance the membrane permeation of the peptide and stabilize it to metabolism.
Methods: Conversion to the linear hexapeptide was studied at 37 degrees C in aqueous buffered solutions and in various biological milieus having measurable esterase activities. Transport and metabolism characteristics were assessed using the Caco-2 cell culture model.
Results: In buffered solutions the cyclic prodrug degraded chemically to the linear hexapeptide in stoichiometric amounts. Maximum stability was observed between pH 3-4. In 90% human plasma (t1/2 = 100 +/- 4 min) and in homogenates of the rat intestinal mucosa (t1/2 = 136 +/- 4 min) and rat liver (t1/2 = 65 +/- 3 min), the cyclic prodrug disappeared faster than in buffered solution, pH 7.4 (t1/2 = 206 +/- 11 min). Pretreatment of these media with paraoxon significantly decreased the degradation rate of the prodrug. When applied to the apical side of Caco-2 cell monolayers, the cyclic prodrug (t1/2 = 282 +/- 25 min) was significantly more stable than the hexapeptide (t1/2 = 14 min) and at least 76-fold more able to permeate (Papp = 1.30 +/- 0.15 x 10(-7) cm/s) than the parent peptide (Papp < or = 0.17 x 10(-8) cm/s).
Conclusions: Preparation of a cyclic peptide using an acyloxyalkoxy promoiety reduced the lability of the peptide to peptidase metabolism and substantially increased its permeation through biological membranes. In various biological media the parent peptide was released from the prodrug by an apparent esterase-catalyzed reaction, sensitive to paraoxon inhibition.
Similar articles
-
Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.Pharm Res. 1999 Jan;16(1):16-23. doi: 10.1023/a:1018802324759. Pharm Res. 1999. PMID: 9950273
-
Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide.Pharm Res. 1997 Jan;14(1):11-7. doi: 10.1023/a:1012091014242. Pharm Res. 1997. PMID: 9034215
-
Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.Pharm Res. 1999 Jan;16(1):24-9. doi: 10.1023/a:1018854308829. Pharm Res. 1999. PMID: 9950274
-
Medoxomil Prodrug Strategies.J Med Chem. 2025 May 8;68(9):9025-9036. doi: 10.1021/acs.jmedchem.4c02967. Epub 2025 Apr 22. J Med Chem. 2025. PMID: 40261681 Review.
-
Design Principles for Intestinal Permeability of Cyclic Peptides.Methods Mol Biol. 2019;2001:1-15. doi: 10.1007/978-1-4939-9504-2_1. Methods Mol Biol. 2019. PMID: 31134564 Review.
Cited by
-
The effect of beta-turn structure on the permeation of peptides across monolayers of bovine brain microvessel endothelial cells.Pharm Res. 1997 Oct;14(10):1341-8. doi: 10.1023/a:1012104301773. Pharm Res. 1997. PMID: 9358545
-
The protein kinase A pathway contributes to Hg2+-induced alterations in phosphorylation and subcellular distribution of occludin associated with increased tight junction permeability of salivary epithelial cell monolayers.J Pharmacol Exp Ther. 2008 Sep;326(3):829-37. doi: 10.1124/jpet.107.135798. Epub 2008 Jun 12. J Pharmacol Exp Ther. 2008. PMID: 18550693 Free PMC article.
-
Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.Pharm Res. 1999 Jan;16(1):7-15. doi: 10.1023/a:1018828207920. Pharm Res. 1999. PMID: 9950272
-
A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics.Pharm Res. 1998 Aug;15(8):1174-81. doi: 10.1023/a:1011975404789. Pharm Res. 1998. PMID: 9706046
-
Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.Pharm Res. 1999 Jan;16(1):16-23. doi: 10.1023/a:1018802324759. Pharm Res. 1999. PMID: 9950273
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources